CompletedPhase 3NCT02094586
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
Studying Cholera
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bavarian Nordic
- Principal Investigator
- James McCarty, MDEmergent Travel Health Inc.
- Intervention
- PXVX0200 Lot A(biological)
- Enrollment
- 3146 enrolled
- Eligibility
- 18-45 years · All sexes
- Timeline
- 2014 – 2015
Study locations (25)
- Coastal Clinical Research, Mobile, Alabama, United States
- Clinical Reseach Consortium Arizona, Phoenix, Arizona, United States
- Avail Clinical Research, DeLand, Florida, United States
- Miami Research Associates, Miami, Florida, United States
- Palm Beach Research, West Palm Beach, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Johnson County Clin-Trials, Lenexa, Kansas, United States
- Heartland Research Associates, Wichita, Kansas, United States
- Central Kentucky Research, Lexington, Kentucky, United States
- University of Kentucky, Lexington, Kentucky, United States
- Boston University, Boston, Massachusetts, United States
- Center for Pharmaceutical Research, Kansas City, Missouri, United States
- St. Louis University, St Louis, Missouri, United States
- Clinical Research Consortium Las Vegas, Las Vegas, Nevada, United States
- Rochester Clinical Research, Rochester, New York, United States
- +10 more locations on ClinicalTrials.gov
Collaborators
Emergent BioSolutions
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02094586 on ClinicalTrials.govOther trials for Cholera
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07509047Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and ChildrenInternational Vaccine Institute
- RECRUITINGPHASE4NCT07487077Extended Dosing Intervals Trial for Oral Cholera Vaccine, KenyaAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT07304284Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-PlusInternational Vaccine Institute
- RECRUITINGNANCT06455852Vaccine- and Infection-derived Correlates of Protection for Cholera.Massachusetts General Hospital
- RECRUITINGNANCT06498817Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)Johns Hopkins Bloomberg School of Public Health
- RECRUITINGNANCT06003816Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)Johns Hopkins Bloomberg School of Public Health
- RECRUITINGNANCT05166850Preventative Intervention for Cholera for 7 DaysJohns Hopkins Bloomberg School of Public Health
- ACTIVE NOT RECRUITINGPHASE2NCT04326478Single Dose Azithromycin to Prevent Cholera in ChildrenMassachusetts General Hospital